NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03164382,"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma",https://clinicaltrials.gov/study/NCT03164382,,COMPLETED,"This trial was designed to investigate whether the survival outcome, response rate and safety of hepatic arterial infusion of oxaliplatin, fluorouracil/leucovorin regimens for patients with Barcelona-Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma was superior than those of the standard treatment with sorafenib or not.",NO,Liver Cancer|Hepatic Carcinoma,DRUG: FOLFOX regimen|DRUG: Sorafenib 200Mg Tab,"Overall survival, Overall survival was the length of time after treatment until death from any cause., 1 months","Time to Progression, Time to Progression was defined as the time from commencement of treatment to radiological disease progression., 1 months|Time to Intrahepatic tumor Progression, Time to Intrahepatic tumor Progression was defined as the time from commencement of treatment to radiological intrahepatic tumor progression., 1 months",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,262,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,SB5010-2017-015,2017-03-01,2020-10-31,2020-11-30,2017-05-23,,2020-12-16,"Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, 500060, China",
